Development of drugs based on imidazole and benzimidazole bioactive heterocycles: Recent advances and future directions

Medicinal Chemistry Research

Volumn 25, Issue 2, 2016, Pages 173-210

  Gaba, Monika ^a,b   Mohan, Chander ^b  

^a Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy   (India)

^b I K GUJRAL PUNJAB TECHNICAL UNIVERSITY   (India)

Author keywords

Benzimidazole; Development; Drug discovery; Imidazole; Medicinal chemistry

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHELMINTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ANTIULCER AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; HISTAMINE; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; NITROGEN; PROTON PUMP INHIBITOR; SEROTONIN ANTAGONIST;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG STRUCTURE; ELECTRON; ENVIRONMENT; HUMAN; MEDICINAL CHEMISTRY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 84954367379     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-015-1495-5     Document Type: Article

References (178)

1. Actor P, Anderson EL, DiCuollo CJ, Ferlanto RJ, Hoover JRE, Pagano JF, Ravin LR, Scheidy SF, Stedman RJ, Theodorides VJ (1967) New broad spectrum anthelmintic, methyl 5(6)-butyl-2-benzimidazolecarbamate. Nature 215:321-322
2. Alomar A, Videla S, Delgadillo J, Gich I, Izquierdo I, Forn J (1995) Flutrimazole 1 % dermal cream in the treatment of dermatomycoses: a multicenter, double-blind, randomized, comparative clinical trial with bifonazole 1 % cream. Efficacy of flutrimazole 1 % dermal cream in dermatomycoses. Catalan flutrimazole study group. Dermatology 190:295-300
3. 3 of histamine receptor. Invest Radiol 23:S130-S132
4. Aulakh GK, Sodhi RK, Singh M (2007) An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci 81:615-639
5. Barker HA, Smyth RD, Weissbach H, Toohey JI, Ladd JN, Volcani BE (1960) Isolation and properties of crystalline cobamide coenzymes containing benzimidazole or 5,6 dimethylbenzimidazole. J Biol Chem 235:480-488
6. 3 receptor-the relationship between structure and function. Neuropharmacology 56:273-284
7. Beck DE, Agama K, Marchand C, Chergui A, Pommier Y, Cushman M (2014) Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents Indotecan (LMP400) and Indimitecan (LMP776). J Med Chem 57:1495-1512
8. Belch JJ, Cormie J, Newman P, McLaren M, Barbenel J, Capell H, Leiberman P, Forbes CD, Prentice CR (1983) Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. Br J Clin Pharmacol 15:113S-116S
9. Bennett JE (1981) Miconazole in cryptococcosis and systemic candidiasis: a word of caution. Ann Intern Med 94:708-709
10. Bhatnagar A, Sharma PK, Kumar N (2011) A review on "Imidazoles": their chemistry and pharmacological potentials. Int J PharmTech Res 3:268-282
11. 4 receptor: a novel therapeutic target for immune and allergic responses. Mini Rev Med Chem 10:1293-1308
12. Bielory L, Lien KW, Bigelsen S (2005) Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 65:215-228
13. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA III, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94: a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 46:2365-2372
14. 2-receptors. Nature 236:385-390
15. Blum AL, Shah G, St Pierre T, Helander HF, Sung CP, Wiebelhaus VD, Sachs G (1971) Properties of soluble ATPase of gastric mucosa. Biochim Biophys Acta 249:101-111
16. 2-receptor antagonist. Gastroenterology 74:339-347
17. Brown HD, Matzuk AR, Ilves IR, Peterson LH, Harris SA, Sarett LH, Egerton JR, Yakstis JJ, Campbell WC, Cuckler AC (1961) Antiparasitic drugs. IV. 2-(4'-Thiazolyl)-benzimidazole, a new anthelmintic. J Am Chem Soc 83:1764-1765
18. Burgess MA, Bodey GP (1972) Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies. Antimicrob Agents Chemother 2:423-426
19. Burnier M (2001) Angiotensin II type 1 receptor blockers. Circulation 103:904-912
20. Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet 355:637-645
21. 3 receptors. Br J Pharmacol 94:397-412
22. Carini DJ, Duncia JV, Aldrich PE, Chiu AT, Johnson AL, Pierce ME, Price WA, Santella JB III, Wells GJ, Wexler RR, Wong PC, Yoo S, Timmermans PBMWM (1991) Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. J Med Chem 34:2525-2547
23. Chang H, Saccomani G, Rabon E, Schackmann R, Sachs G (1977) Proton transport by gastric membrane vesicles. Biochim Biophys Acta 464:313-327
24. Chey WD, Cash BD (2005) Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhea. Expert Opin Investig Drugs 14:185-193
25. Chodosh LA, Fire A, Samuels M, Sharp PA (1989) 5,6-Dichloro-1-beta-D- ribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro. J Biol Chem 264:2250-2257
26. 3 receptors in the feeding-related hypothalamic ventromedial nucleus. Br J Pharmacol 167:1099-1110
27. Clarke RW, Harris J (2002) RX 821002 as a tool for physiological investigation of alpha(2)- adrenoceptors. CNS Drug Rev 8:177-192
28. Cooper DS (1984) Antithyroid drugs. N Engl J Med 311:1353-1362
29. 1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs RD 6:371-384
30. 4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. Eur J Pharmacol 563:240-244
31. Cosar C, Julou L (1959) The activity of 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole (R.P. 8823) against experimental Trichomonas vaginalis infections. Ann Inst Pasteur 96:238-241
32. DeRemer DL, Katsanevas K, Ustun C (2011) Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia. Cancer Manag Res 3:65-78
33. DeSimone RW, Currie KS, Mitchell SA, Darrow JW, Pippin DA (2004) Privileged structures: applications in drug discovery. Comb Chem High T Scr 7:473-494
34. Diacon AH, Dawson R, Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Niekerk C, Everitt D, Hutchings J, Burger DA, Schall R, Mendel CM (2015) Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 191:943-953
35. DoCampo R (1990) Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 73:1-27
36. Elizabeth B, Lurie P, Wolfe SM (2000) Alosetron for irritable bowel syndrome. Lancet 356:2009
37. Emerson CR, Marzella N (2010) Dexlansoprazole: a proton pump inhibitor with a dual delayed- release system. Clin Ther 32:1578-1596
38. Fainstein V, Bodey GP (1980) Cardiorespiratory toxicity due to miconazole. Ann Intern Med 93:432-433
39. Fei F, Zhou Z (2013) New substituted benzimidazole derivatives: a patent review (2010-2012). Expert Opin Ther Pat 23:1157-1179
40. +) ATPase. Nature 290:159-161
41. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386
42. Fernandez-Torres B, Inza I, Guarro J (2003) In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes. J Clin Microbiol 41:5209-5211
43. Fisher MH (1986) Chemistry of antinematodal agents. In: Campbell WC, Rew RS (eds) Chemotherapy of parasitic diseases. Plenum Press, New York, pp 239-266
44. Freston JW (1982) Cimetidine. I. developments, pharmacology, and efficacy. Ann Intern Med 97:573-580
45. Fromtling RA (1986) Butoconazole: a new antifungal agent. Rev Recent Work. Drugs Today 22:261-263
46. Fromtling RA (1988) Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1:187-217
47. Gaba M, Singh D, Singh S, Sharma V, Gaba P (2010) Synthesis and pharmacological evaluation of novel 5-substituted-1-(phenylsulphonyl)-2-methylbenzimidazole derivatives as anti- inflammatory and analgesic Agents. Eur J Med Chem 45:2245-2249
48. Gaba M, Singh S, Mohan C (2014) Benzimidazole: an emerging scaffold for analgesic and anti- inflammatory agents. Eur J Med Chem 76:494-505
49. Gaba M, Gaba P, Uppal D, Dhingra N, Bahia MS, Silakari O, Mohan C (2015) Benzimidazole derivatives: search for GI-friendly anti-inflammatory analgesic agents. Acta Pharm Sin B 5:337-342
50. Gaddum JH, Picarelli ZP (1957) Two kinds of tryptamine receptor. Br J Pharmacol Chemother 12:323-328
51. Gerra G, Zaimovic A, Giusti F, Gennaro CD, Zambelli U, Gardini S, Delsignore R (2001) Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat 21:11-17
52. Gewurz BE, Jacobs M, Proper JA, Dahl TA, Fujiwara T, Dezube BJ (2004) Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study. J Infect Dis 190:1957-1961
53. 4 receptor activity of conformationally restricted cyanoguanidines related to UR-PI376. Arch Pharm 344:775-785
54. Giese JL, Stanley TH (1983) Etomidate: a new intravenous anesthetic induction agent. Pharmacotherapy 3:251-258
55. Godefroi EF, Heeres J, Van Cutsem J, Janssen PA (1969) The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem 12:784-791
56. Gordon SG, Miller MW, Saunders AB (2006) Pimobendan in heart failure therapy-a silver bullet. J Am Anim Hosp Assoc 42:90-93
57. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing XJ, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Lakshmi PK, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-243
58. Griffith RK (2003) Adrenergics and adrenergic-blocking agents. In: Abraham DJ (ed) Burger's medicinal chemistry and drug discovery. Wiley, Hoboken, pp 1-37
59. Hartmann M, Zimmer CH (1972) Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393 and 3943. Biochim Biophys Acta 287:386-389
60. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W (2002) Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45:1757-1766
61. Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, Cairns C, Collins J, Rodgers C, McElnay JC (2008) Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol 66:517-528
62. Heel RC, Brogden RN, Parke GE, Speight TM, Avery GS (1980) Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 19:7-30
63. Heeres J, Backx LJ, Mostmans JH, Van Cutsem J (1979) Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad- spectrum antifungal agent. J Med Chem 22:1003-1005
64. Heinz BA, Vance LM (1995) The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol 69:74189-74197
65. +ATPase inhibitors. Elsevier Science BV, pp 233-264
66. Hernandez Molina JM, Llosa J, Martinez Brocal A, Ventosa A (1992) In vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp. Mycopathalogia 118:15-21
67. Hoff DR (1982) In: Bindra JS, Lednicer D (eds) Chronicles of drug discovery. Wiley, New York, pp 239-256
68. Hoff DR, Fisher MH, Bochis RJ, Lusi RJ, Waksmunski A, Egerton RJ, Yastis JJ, Cuckler AC, Campbell WC (1970) A new broad spectrum anthelmintic: 2-(4-thiazolyl)-iso- propoxycarbonyl aminobenzimidazole. Experientia 26:550-552
69. Hough LB (2001) Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 59:415-419
70. http://www.healthline.com/health/parasitic-infections#Overview1
71. http://www.lef.org/protocols/infections/fungal-infections-candida-01.htm
72. http://www.dddmag.com/news/2012/08/ferrer-files-arasertaconazole-ind
73. 4 receptor agonists. Bioorg Med Chem Lett 20:7191-7199
74. Ingle RG, Magar DD (2011) Heterocyclic chemistry of benzimidazoles and potential activities of derivatives. Int J Drug Res Tech 1:26-32
75. Insel PA (1996) Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med 334:580-585
76. Ishikawa H (1999) Mizoribine and mycophenolate mofetil. Curr Med Chem 6:575-597
77. 125I-iodophenpropit, to rat brain. Br J Pharmcol 113:355-362
78. 125Iiodophenpropit. Naunyn-Schmiedeberg Arch Pharmacol 362:60-67
79. Janssen PA, Niemegeers CJ, Schellekens KH, Marsboom RH, Herin VV, Amery WK, Admiraal PV, Bosker JT, Crul JF, Pearce C, Zegveld C (1971) Bezitramide (R 4845), a new potent and orally long-acting analgesic compound. Arzneim Forsch 21:862-867
80. Jarrad AM, Karoli T, Blaskovich MAT, Lyras D, Coope MA (2015) Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J Med Chem 58:5164-5185
81. Jerchel D, Fischer H, Fracht M (1952) Zur Darstellung der benzimidazole. Liebigs Ann Chem 575:162-173
82. Jevons S, Gymer GE, Brammer KW, Cox DA, Leeming MRG (1979) Antifungal activity of tioconazole (UK-20, 349), a new imidazole derivative. Antimicrob Agents Chemother 15:597-602
83. Johns TG, Piper DC, James GW (1979) The pharmacological profile of a potential hypnotic compound RU 31158. Arch Int Pharmacodyn Ther 240:53-65
84. Jones CD, Andrews DM, Barker AJ, Blades K, Daunt P, East S, Geh C, Graham MA, Johnson KM, Loddick SA, McFarland HM, McGregor A, Moss L, Rudge DA, Simpson PB, Swain ML, Tam KY, Tucker JA, Walker M (2008) The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem Lett 18:6369-6373
85. Josephy PD, Palcic B, Skarsgard LD (1981) In vitro metabolism of misonidazole. Br J Cancer 43:443-450
86. Kapetanovic IM, Kupferberg HJ (1984) Nafimidone, an imidazole anticonvulsant, and its metabolite as potent inhibitors of microsomal metabolism of phenytoin and carbamazepine. Drug Metab Dispos 12:560-564
87. Kapoor VK, Chadha R, Venisetty PK, Prasanth S (2003) Medicinal significance of nitroimidazoles: some recent advances. J Sci Ind Res 62:659-665
88. Kath R, Blumenstengel K, Fricke HJ, Hoffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48-54
89. Kemp KM, Henderlight L, Neville M (2008) Pre-cedex: is it the future of cooperative sedation? Crit Care Insider 38:50-55
90. Khabnadideh S, Rezaei Z, Khalafi NA, Motazedian MH, Eskandari M (2007) Synthesis of metronidazole derivatives as antigiardiasis agents. DARU J Pharm Sci 15:17-20
91. Kitbunnadaj R, Zuiderveld OP, Christophe B, Hulscher S, Menge WM, Gelens E, Snip E, Bakker RA, Celanire S, Gillard M, Talaga P, Timmerman H, Leurs R (2004) Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist. J Med Chem 47:2414-2417
92. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T (1996) Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 39:5228-5235
93. Kromer W (1995) Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 56:443-454
94. Kupietzky A, Houpt MI (1993) Midazolam: a review of its use for conscious sedation of children. Pediatr Dent 15:237-241
95. 3 receptor drugs. Nat Rev Drug Discov 4:107-120
96. Li EC, Davis LE (2003) Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25:2669-2708
97. Lindberg P, Carlsson E (2006) Analogue-based drug discovery. In: Fischer J, Ganellin CR (eds) Esomeprazole in the framework of proton-pump inhibitor development. Wiley-VCH Verlag, Weinheim, pp 81-113
98. Lutwick L, Rytel MW, Yanez JP, Galgiani JN, Stevens DA (1979) Deep infections from Petriellidium boydii treated with miconazole. J Am Med Assoc 241:271-272
99. Martin RJ (1997) Modes of action of anthelmintic drugs. Vet J 154:11-34
100. McCracken RO, Lipkowitz KB (1990) Structure-activity relationships of benzothiazole and benzimidazole anthelmintics: a molecular modeling approach to in vivo drug efficacy. J Parasitol 76:853-864
101. McFarland JW (1972) The chemotherapy of intestinal nematodes. Prog Drug Res 16:157-193
102. Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K (2013) Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of condensation. Hypertens Res 36:134-139
103. Morris STW, Reid JL (1997) Moxonidine: a review. J Hum Hypertens 11:629-635
104. 3-receptor antagonist/inverse agonist, modulates methamphetamine-induced sensitization in mice. Eur J Neurosci 33:1197-1204
105. Munson K, Garcia R, Sachs G (2005) Inhibitor and ion binding sites on the gastric H, K- ATPase. Biochemistry 44:5267-5284
106. Naik P, Murumkar P, Giridhar R, Yadav MR (2010) Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists-a perspective. Bioorg Med Chem 18:8418-8456
107. Nakamura S (1955) Structure of azomycin, a new antibiotic. Pharm Bull 3:379-383
108. 3 receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats. Eur J Pharmacol 15:88-92
109. Narasimhan B, Sharma D, Kumar P (2011) Biological importance of imidazole nucleus in the new millennium. Med Chem Res 20:1119-1140
110. Nimura K, Niwano Y, Ishiduka S, Fukumoto R (2001) Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan. Int J Antimicrob Agents 18:173-178
111. Njar VC, Brodie AM (2015) Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem 58:2077-2087
112. Ogata M, Matsumoto H, Hamada Y, Takehara M, Tawara K (1983) 1-[1-[2-[(3-chlorobenzyl) oxy] phenyl] vinyl]-1H-imidazole hydrochloride, a new potent antifungal agent. J Med Chem 26:768-770
113. Olbe L, Carlsson E, Lindberg P (2003) A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2:132-139
114. Ortiz JA (1992) Sertaconazole (FI-7045). A new antifungal agent. Arzneim Forsch 42:689-690
115. Ozkay Y, Tunali Y, Karaca H, Isikdag I (2010) Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety. Eur J Med Chem 45:3293-3298
116. Palacin C, Tarrago C, Agut J, Guglietta A (2001) In vitro activity of sertaconazole, ketoconazole, fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeast infections. Methods Find Exp Clin Pharmacol 23:61-64
117. Parsons ME, Ganellin CR (2006) Histamine and its receptors. Br J Pharmacol 147:S127-S135
118. Pectasides D, Yianniotis H, Alevizakos N, Bafaloukos D, Barbounis V, Varthalitis J, Dimitriadis M, Athanassiou A (1989) Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Br J Cancer 60:627-629
119. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, Luo Y, Giranda VL (2009) Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)- 2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52:514-523
120. Pertovaara A, Haapalinna A, Sirvio J, Virtanen R (2005) Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev 11:273-288
121. Plempel M, Regel E, Buchel KH (1983) Antimycotic efficacy of bifonazole in vitro and in vivo. Arzneimittelforschung 33:517-524
122. Polak A (1982) Oxiconazole, a new imidazole derivative. Evaluation of antifungal activity in vitro and in vivo. Arzneimittelforschung 32:17-24
123. Prakash A, Lamb HM (1998) Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria. BioDrugs 10:41-63
124. Raats JI, Falkson G, Falkson HC (1992) A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 10:111-116
125. 3 receptor antagonist for the control of nausea and vomiting. Drugs Today 38:75-89
126. Radziszewski B (1882) Ueber die Constitution des Lophins und verwandter Verbindungen. Chem Ber 15:1493-1496
127. Ren J, Nichols C, Bird LE, Fujiwara T, Sugimoto H, Stuart DI, Stammers DK (2000) Binding of the second generation nonnucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem 275:14316-14320
128. Rezaei Z, Khabnadideh S, Zomorodian K, Pakshir K, Kashi G, Sanagoei N, Gholami S (2011) Design, synthesis and antifungal activity of some new imidazole and triazole derivatives. Arch Pharm Chem Life Sci 344:658-665
129. +-ATPase: the site of action of omeprazole. Scand J Gatroenterol 66:3-11
130. Sachs G, Collier RH, Schoemaker RL, Hirschowitz BI (1968) The energy source of gastric acid secretion. Biochim Biophys Acta 162:210-219
131. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K (2007) The gastric H, K ATPase as a drug target. J Clin Gastroenterol 41:S226-S242
132. 3 receptor antagonists go to clinics. Biol Pharm Bull 31:2163-2181
133. Savic I, Widen L, Stone-Elander S (1991) Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 337:133-137
134. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of parkinson's disease. Mov Disord 18:872-883
135. Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery (1975) Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs 9:424-447
136. Scarpignato C, Hunt RH (2008) Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol 8:677-684
137. Scheinfeld N (2003) Cimetidine: a review of the recent developments and reports in cutaneous medicine. Dermatol Online J 9:4
138. Schimke K, Davis TM (2007) Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes. Curr Opin Investig Drugs 8:338-344
139. Senn-Bilfinger J, Sturm E (2006) Analogue-based drug discovery. In: Fischer J, Ganellin CR (eds) The development of a new proton-pump inhibitor: The case history of pantoprazole. Wiley-VCH Verlag, Weinheim, pp 115-136
140. Shadomy S (1971) In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun 4:143-148
141. Sharma S (1990) Vector-borne diseases. Prog Drug Res 35:365-485
142. Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79
143. Shin JM, Sachs G (2009) Long lasting inhibitors of the gastric H, K-ATPase. Expert Rev Clin Pharmacol 2:461-468
144. +-K-ATPase: structure, function, and inhibition. Pflug Arch Eur J Phy 457:609-622
145. Shinn DLS (1962) Metronidazole in acute ulcerative gingivitis. Lancet 279:1191
146. 3 receptor function and ligands: recent developments. Mini Rev Med Chem 13:47-57
147. Spasov AA, Yozhitsa IN, Bugaeva LI, Anisimova VA (1999) Benzimidazole derivatives: spectrum of pharmacological activity and toxicological properties. Pharm Chem J 33:232-243
148. Stahle H (2000) A historical perspective: development of clonidine. Baillieres Clin Anaesthesiol 14:237-246
149. 4 receptor ligands. Expert Opin Ther Pat 13:851-865
150. Stringer A, Wright MA (1976) The toxicity of benomyl and some related 2-substituted benzimidazoles to the earthworm Lumbricus terrestris. Pest Sci 7:459-464
151. Sun L, Li D, Dong X, Yu H, Dong JT, Zhang C, Lu X, Zhou J (2008) Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells. Biochem Pharmacol 75:1027-1034
152. Tageja N, Nagi J (2010) Bendamustine: something old, something new. Cancer Chemother Pharmacol 66:413-423
153. Tajana A, Sibilia C, Cappelletti R, Cova A, Nardi D (1981) Physico-chemical, structural and analytical studies on fenticonazole, a new drug with antimycotic properties. Arzneim Forsch 31:2127-2133
154. Tarral A, Blesson S, Mordt OV, Torreele E, Sassella D, Bray MA, Hovsepian L, Evene E, Gualano V, Felices M, Strub-Wourgaft N (2014) Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet 53:565-580
155. Tettenborn D (1974) Toxicity of clotrimazole. Postgrad Med J 50:17-20
156. Thiele K, Zirngibl L, Pfenniger MH, Egli M, Dobler M (1987) Antimycotic imidazolyl-alkenes Synthesis and X-ray crystal structure of omoconazole. Helv Chim Acta 70:441-444
157. Thomas X, Elhamri M (2007) Tipifarnib in the treatment of acute myeloid leukemia. Biologics 1:415-424
158. 4 receptors as novel drug targets. Expert Opin Invest Drugs 18:1519-1531
159. Townsendand LB, Wise DS (1990) The synthesis and chemistry of certain anthelmintic benzimidazoles. Parasitol Today 6:107-112
160. Uchida K, Nishiyama Y, Yamaguchi H (2004) In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 10:216-219
161. Unger T, Scholkens BA (ed), Angiotensin Vol. II, Maillard M, Burnier M, Clinical pharmacology of angiotensin II receptor antagonists, Springer:Berlin. (2004) pp 454-476
162. Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG (2015) In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:136-144
163. Vahlquist A, Blockhuys S, Steijlen P, Van Rossem K, Didona B, Blanco D, Traupe H (2014) Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial. Br J Dermatol 170:173-181
164. Vanden Bossche H (1974) Biochemical effects of miconazole on fungi. Biochem Pharmacol 23:887-899
165. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB Jr, Fowler WC, Raleigh JA (1998) Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71:270-277
166. Weide R (2008) Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma. Ther Clin Risk Manag 4:727-732
167. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PB (1996) Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 39:625-656
168. Woolley DW (1944) Some biological effects produced by benzimidazole and their reversal by purines. J Biol Chem 152:225-232
169. Wright JB (1951) The chemistry of the benzimidazoles. Chem Rev 48:397-541
170. Xavier AS, Lakshmanan M (2014) Delamanid: a new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother 5:222-224
171. Yadav G, Ganguly S (2015) Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: a mini-review. Eur J Med Chem 97:419-443
172. Yanagiasawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, Sada T, Mizuno M, Ikeda M, Miyamoto S, Furukawa Y, Koike H (1996) Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J Med Chem 39:323-338
173. Yanagisawa H, Koike H, Miura S (2012) Case studies in modern drug discovery and development. In: Huang X, Aslanian RG (eds) Olmesartan medoxomil: an angiotensin II receptor blocker. Wiley, USA, pp 46-64
174. Yang Y, Jin C, Li H, He Y, Liu Z, Bai L, Dou K (2012) Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo. Exp Ther Med 3:299-303
175. Yoshida H, Kasuga O, Yamaguchi T (1984) Studies on antifungal activities of sulconazole. Chemotherapy 32:477-484
176. 4 receptor ligands. Landes Bioscience. Springer, Berlin, pp 125-140
177. Zajac P, Holbrook A, Super ME, Vogt M (2013) An overview: current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia. Osteopath Fam Physician 5:79-85
178. Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT (1999) Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethyl astemizole and nor astemizole. J Cardiovasc Electrophysiol 10:836-843